Pasithea Therapeutics Corp.
Clinical trials sponsored by Pasithea Therapeutics Corp., explained in plain language.
-
New pill tested to shrink painful NF1 tumors
Disease control Recruiting nowThis early-stage study is testing a new oral medication called PAS-004 in adults with Neurofibromatosis Type 1 (NF1) who have painful, inoperable, or recurring plexiform neurofibroma tumors. The main goals are to find a safe dose, understand the side effects, and see if the drug …
Phase: PHASE1 • Sponsor: Pasithea Therapeutics Corp. • Aim: Disease control
Last updated Apr 01, 2026 14:41 UTC
-
New oral cancer drug enters first human safety testing
Disease control Recruiting nowThis is the first study in humans testing PAS-004, an oral medication designed to target specific genetic mutations found in advanced solid tumors. The main goal is to find a safe dose and understand side effects in 48 adults whose cancers have progressed despite standard treatme…
Phase: PHASE1 • Sponsor: Pasithea Therapeutics Corp. • Aim: Disease control
Last updated Mar 30, 2026 14:30 UTC